Engineered immune cells take aim at Hard-to-Treat lupus kidney disease

This early study tests a new treatment called CHT105 for people with lupus nephritis that hasn't responded to standard therapies. CHT105 uses specially engineered immune cells from healthy donors to target and destroy the faulty immune cells driving the disease. The main goals are to check if the treatment is safe and to see if it can improve kidney function. The study involves 14 adults who will receive a single infusion and be followed for up to 15 years.